MedTrace Logo

Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion

NCT03275792 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-11-09

No results posted yet for this study

Summary

This study will provide feasibility data regarding the conduct of a clinical trail evaluating the use of early aggressive inpatient intravenous rehydration in children with Shiga Toxin producing E. coli infection.

Conditions

  • Hemolytic-Uremic Syndrome

Interventions

DRUG

D5-0.9%NS

Admission for intravascular volume expansion

DRUG

Routine home oral rehydration

Routine oral fluids as is given at home to all children with acute diarrheal disease

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Stephen Freedman, MDCM, MSc · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275792 on ClinicalTrials.gov